CompletedPhase 1NCT01093508

Single-dose Safety Study of APD916 in Healthy Volunteers

Studying Narcolepsy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Arena Pharmaceuticals
Principal Investigator
James Maynard, MD
Community Research, Cincinnati, OH
Intervention
APD916(drug)
Enrollment
72 enrolled
Eligibility
18-45 years · All sexes
Timeline
20102010

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01093508 on ClinicalTrials.gov

Other trials for Narcolepsy

Additional recruiting or active studies for the same condition.

See all trials for Narcolepsy

← Back to all trials